Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein

De Maat, 2003, Drug interactions between antiretroviral drugs and comedicated agents, Clin Pharmacokinet, 42, 223, 10.2165/00003088-200342030-00002 Piscitelli, 2001, Interactions among drugs for HIV and opportunistic infections, N Engl J Med, 344, 984, 10.1056/NEJM200103293441307 Van Heeswijk, 2001, Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetic and clinical experience, Antivir Ther, 6, 201, 10.1177/135965350200600401 Antoniou, 2005, Interactions between antiretrovirals and antineoplastic drug therapy, Clin Pharmacokinet, 44, 111, 10.2165/00003088-200544020-00001 Sankatsing, 2004, P-glycoprotein in human immunodeficiency virus type 1 infection and therapy, Antimicrob Agents Ther, 48, 1073, 10.1128/AAC.48.4.1073-1081.2004 Dasgupta, 2001, Pharmacokinetic and other drug interactions in patients with AIDS, Ther Drug Monit, 23, 591, 10.1097/00007691-200112000-00001 Schinkel, 2003, Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview, Adv Drug Deliv Rev, 55, 3, 10.1016/S0169-409X(02)00169-2 Yu, 1999, The contribution of P-glycoprotein to pharmacokinetic drug–drug interactions, J Clin Pharmacol, 39, 1203, 10.1177/00912709922012006 Lee, 1998, HIV-1 Protease inhibitors are substrates for the MDR1 multidrug transporter, Biochemistry, 37, 3594, 10.1021/bi972709x Profit, 1999, Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors, AIDS, 13, 1623, 10.1097/00002030-199909100-00004 Huisman, 2001, P-glycoprotein limits oral availability, brain and fetal penetration of saquinavir even with high doses of ritonavir, Mol Pharmacol, 59, 806, 10.1124/mol.59.4.806 Perloff, 2001, Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line, J Pharm Sci, 90, 1829, 10.1002/jps.1133 Perloff, 2005, Atazanavir: effects on P-Glycoprotein transport and CYP3A metabolism in vitro, Drug Metab Dispos, 33, 764, 10.1124/dmd.104.002931 Huang, 2001, Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors, Drug Metab Dispos, 29, 754 Mukwaya, 2005, Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers, Antimicrob Agents Chemother, 49, 4903, 10.1128/AAC.49.12.4903-4910.2005 Amsden, 2000, A study of the pharmacokinetics of azithromycin and nelfinavir when coadministerd in healthy volunteers, J Clin Pharmacol, 40, 1522, 10.1177/009127000004001226 Ding, 2004, Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers, Clin Pharmacol Ther, 76, 73, 10.1016/j.clpt.2004.02.008 Stormer, 2002, Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture, Pharm Res, 19, 1038, 10.1023/A:1016430825740 Chandler, 2003, The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro, J Acquir Immune Defic Syndr, 33, 551, 10.1097/00126334-200308150-00001 Antonelli, 1992, Resistance of HIV-1 to AZT might also involve the cellular expression of multidrug resistance P-glycoprotein, AIDS Res Hum Retroviruses, 8, 1839, 10.1089/aid.1992.8.1839 Leung, 1999, Role of P-glycoprotein in the renal transport of dideoxynucleoside analog drugs, Can J Physiol Pharmacol, 77, 625, 10.1139/y99-059 Jorajuria, 2004, ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages, Antivir Ther, 9, 519, 10.1177/135965350400900403 Ray, 2006, Mechanism of active renal tubular efflux of tenofovir, Antimicrob Agents Chemother, 50, 3297, 10.1128/AAC.00251-06 Ray, 2006, Role of intestinal absorption in increased tenofovir exposure when tenofovir disoproxil fumarate is co-administered with atazanavir or lopinavir/ritonavir Van Gelder, 2002, Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures, Drug Metab Dispos, 30, 924, 10.1124/dmd.30.8.924 Schinkel, 1995, Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A, J Clin Invest, 96, 1698, 10.1172/JCI118214 Weiss, 2003, Inhibition of P-glycoprotein by newer antidepressants, J Pharmacol Exp Ther, 305, 197, 10.1124/jpet.102.046532 Boesch, 1991, In vivo circumvention of P-glycoprotein mediated multidrug resistance of tumor cells with SDZ PSC 833, Cancer Res, 51, 4226 Fröhlich, 2004, In vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins, Biochem Pharmacol, 68, 2409, 10.1016/j.bcp.2004.08.026 Albermann, 2005, Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver, Biochem Pharmacol, 70, 949, 10.1016/j.bcp.2005.06.018 Weiss, 2006, Evaluation of inhibitory potencies for compounds inhibiting P-glycoprotein but without maximum effects: F2 values, Drug Metab Dispos, 34, 203, 10.1124/dmd.105.007377 Shiraki, 2000, Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins, Biol Pharm Bull, 23, 1528, 10.1248/bpb.23.1528 Washington, 1998, Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells, J Acquir Immune Defic Syndr, 19, 203, 10.1097/00042560-199811010-00001 Weiss, 2002, Poor solubility limiting significance of in-vitro studies with HIV protease inhibitors, AIDS, 16, 674, 10.1097/00002030-200203080-00024 Bachmeier, 2005, Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood–brain barrier, Pharm Res, 22, 1259, 10.1007/s11095-005-5271-y Penzak, 2004, Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes, Ther Drug Monit, 26, 322, 10.1097/00007691-200406000-00018 Van Praag, 2000, Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir, AIDS, 14, 1187, 10.1097/00002030-200006160-00016 Van Heeswijk, 2006, Time-dependent interaction between lopinavir/ritonavir and fexofenadine, J Clin Pharmacol, 46, 758, 10.1177/0091270006288733 Kim, 1998, The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors, J Clin Invest, 101, 289, 10.1172/JCI1269 Huisman, 2000, Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors, AIDS, 14, 237, 10.1097/00002030-200002180-00005 Janneh, 2005, Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP, AIDS, 19, 2097, 10.1097/01.aids.0000194793.36175.40 Almond, 2005, Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals, J Antimicrob Chemother, 56, 738, 10.1093/jac/dki308 Glynn, 1998, In vitro blood–brain barrier permeability of nevirapine compared to other HIV antiretroviral agents, J Pharm Sci, 87, 306, 10.1021/js970291i Dirson, 2006, Efavirenz does not interact with the ABCB1 transporter at the blood–brain barrier, Pharm Res, 23, 1525, 10.1007/s11095-006-0279-5 Berruet, 2005, Effect of efavirenz on intestinal p-glycoprotein and hepatic p450 function in rats, J Pharm Pharm Sci, 8, 226 Von Moltke, 2001, Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors, J Clin Pharmacol, 41, 85, 10.1177/00912700122009728 Holló, 1994, Calcein accumulation as fluorometric assay of th43e multidrug transporter, Biochim Biophys Acta, 1191, 384, 10.1016/0005-2736(94)90190-2 Homolya, 1996, A new method for quantitative assessment of P-glycoprotein-related multidrug resistance in tumour cells, Br J Cancer, 73, 849, 10.1038/bjc.1996.151 Feller, 1995, Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry, Br J Cancer, 72, 543, 10.1038/bjc.1995.371 Crivellato, 2002, The fluorescent probe bodipy-FL-verapamil is a substrate for both P-glycoprotein and multidrug resistance protein (MRP)-1, J Histochem Cytochem, 50, 731, 10.1177/002215540205000514 Honjo, 2001, Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-over-expressing cells, Cancer Res, 61, 6635 Nakanishi, 2003, Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis, Mol Pharmacol, 64, 1452, 10.1124/mol.64.6.1452 Van der Sandt, 2000, Specifity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein function in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines, Eur J Pharm Sci, 11, 207, 10.1016/S0928-0987(00)00097-X Litman, 2000, The multidrug-resistant phenotype associated with over-expression of the new ABC half-transporter MXR (ABCG2), J Cell Sci, 113, 2011, 10.1242/jcs.113.11.2011 Pastan, 1988, A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells, Proc Natl Acad Sci USA, 85, 4486, 10.1073/pnas.85.12.4486 Ehrhardt, 2004, Influence of lipid lowering fibrates on P-glycoprotein activity in vitro, Biochem Pharmacol, 67, 285, 10.1016/j.bcp.2003.09.008